Company Information

  

Address: 87 CAMBRIDGE PARK DRIVE  
City: CAMBRIDGE 
State: MA 
Zip Code: 02140 
Telephone: (617) 401-4060 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company using our proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system. Inappropriate activation of the complement system can quickly turn it from a beneficial defense system to an aggressor that plays a major role in immune and inflammatory diseases. We are developing our lead product candidate, RA101495, a convenient self-administered subcutaneous, or SC, injection, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH. PNH is a rare, chronic, life-threatening, blood disorder where red blood cells are mistakenly attacked and destroyed by the complement system.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/201724.01NA0.61
06/201710.28NA1.82
03/20171.94NA10.97
12/2016-6.98NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.16Total Liab/Total Assets0.08
Net Inc/Total Assets-0.23Total Liab/Inv Cap0.08
Net Inc/Inv Cap-0.24Total Liab/Comm Equity0.05
Pretax Inc/Net Sales-5.86Interest Coverage RatioNA
Net Inc/Net Sales-5.86Curr Debt/EquityNA
Cash Flow/Net Sales-4.43LTD/EquityNA
SG&A/NetSales1.02Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio17.74
Inventory TurnoverNACurrent Ratio17.74
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.04Inv/Curr AssetsNA
Net Sales/PP&E0.89  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.28 2.35 2.47 1.61
Operating Income -15.41 -12.81 -11.48 -10.99
Interest Exp NA NA NA 0.00
Pretax Income -15.28 -12.66 -11.36 -10.91
Other Income 0.14 0.15 0.12 0.09
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -15.28 -12.66 -11.36 -10.89

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 84.09 96.61 105.37 117.81
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 85.21 97.84 107.01 119.50
Net Property, Plant & Equipment 5.97 6.24 6.22 5.54
Total Assets 92.91 105.82 114.98 126.82
Liabilities        
Accounts Payable 7.37 6.58 4.92 6.43
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 7.80 7.00 5.31 6.74
Long-Term Debt NA NA NA NA
Total Liabilities 10.33 9.65 8.06 9.60
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.02 0.02 0.02 0.02
Retained Earnings -108.07 -92.80 -80.14 -68.76
Treasury Stock NA NA NA NA
Total Stockholders' Equity 82.58 96.18 106.92 117.22
Total Liabilities and Stockholders' Equity 92.91 105.82 114.98 126.82

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -12.21 -8.91 -12.00 -9.02
Net Cash Provided by Investing Activities -0.26 -0.65 -0.48 -0.61
Net Cash Provided by Financing Activities -0.04 0.79 0.04 96.25

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20144.83-5.48--
12/20154.09-13.94--
12/20164.93-28.86-6.98
Growth Rates1.01----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/177316,00570.74




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.